147 related articles for article (PubMed ID: 28942006)
1. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
2. Effects of myricetin on the bioavailability of carvedilol in rats.
Lee W; Woo ER; Choi JS
Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
[TBL] [Abstract][Full Text] [Related]
3. Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats.
Lim TH; Cho YA; Choi DH
J Physiol Pharmacol; 2015 Aug; 66(4):591-7. PubMed ID: 26348083
[TBL] [Abstract][Full Text] [Related]
4. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study.
Huang Y; Zheng S; Pan Y; Li T; Xu ZS; Shao MM
J Pharm Biomed Anal; 2016 Sep; 128():184-190. PubMed ID: 27262994
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients.
Nardotto GHB; Lanchote VL; Coelho EB; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S108-S115. PubMed ID: 28522373
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
10. The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats.
Abrudan MB; Muntean DM; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 99(3-4):139-143. PubMed ID: 28052289
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
12. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G
Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
[TBL] [Abstract][Full Text] [Related]
15. Chiral analysis of carvedilol and its metabolites hydroxyphenyl carvedilol and O-desmethyl carvedilol in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical pharmacokinetic study.
Nardotto GHB; Coelho EB; Marques MP; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Mar; 1015-1016():173-180. PubMed ID: 26927877
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
17. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
18. Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats.
Hokama N; Hobara N; Sakai M; Kameya H; Ohshiro S; Sakanashi M
J Pharm Pharmacol; 2002 Jun; 54(6):821-5. PubMed ID: 12078998
[TBL] [Abstract][Full Text] [Related]
19. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
20. Saturable enantioselective first-pass effect for carvedilol after high oral racemate doses in rats.
Stahl E; Henke D; Mutschler E; Spahn-Langguth H
Arch Pharm (Weinheim); 1993 Mar; 326(3):123-5. PubMed ID: 8097624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
